First it was Moderna, then Sanofi, and now Lilly. OpenAI’s influence on the pharmaceutical industry has made its way to Indianapolis.
Lilly Chief Information Officer …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb
The study shows that positive aging expectations correlate with improved cognitive health and reduced subjective decline, emphasizing the role of mindset.
Dive Brief: The Food and Drug Administration granted de novo clearance to an AI tool to help clinicians predict and diagnose sepsis, the first time